Paper · 445479
Inhibition of chemical transformation in C3H/10T1/2 cells by protease inhibitors.
Kuroki T and 1 other. Cancer Res, 1979. Cited by 68 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Inhibition of chemical transformation in C3H/10T1/2 cells by protease inhibitors. Papers, record 445479. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/445479
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Transformation, Neoplastic | Major topic |
| Protease Inhibitors | Major topic |
| Animals | |
| Cell Division | |
| Cells, Cultured | |
| Cricetinae | |
| Cricetulus | |
| Methylcholanthrene | |
| Methylnitronitrosoguanidine | |
| Mice | |
| Mice, Inbred C3H | |
| Mutation |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 68 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7,761,410 | Heritable, population-wide damage to cells as the driving force of neoplastic transformation. | Proc Natl Acad Sci U S A | 1995 | https://conductscience.org/library/papers/7761410 | PubMed |
| 7,437,293 | Inhibiting effects of antipain on urethane-induced lung neoplasia in mice. | Br J Cancer | 1980 | https://conductscience.org/library/papers/7437293 | PubMed |
| 6,935,676 | Antipain inhibits N-methyl-N'-nitro-N-nitrosoguanidine-induced transformation and increases chromosomal aberrations. | Proc Natl Acad Sci U S A | 1980 | https://conductscience.org/library/papers/6935676 | PubMed |
| 6,769,125 | Studies on mechanism of action of anti-tumor-promoting agents: their specificity in two-stage promotion. | Proc Natl Acad Sci U S A | 1980 | https://conductscience.org/library/papers/6769125 | PubMed |
| 4,030,622 | Sodium butyrate induced alterations in lysosomal enzyme activity. | In Vitro Cell Dev Biol | 1985 | https://conductscience.org/library/papers/4030622 | PubMed |
| 3,860,869 | Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray-induced transformation in vitro. | Proc Natl Acad Sci U S A | 1985 | https://conductscience.org/library/papers/3860869 | PubMed |
| 1,557,421 | A growth-regulated protease activity that is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. | Proc Natl Acad Sci U S A | 1992 | https://conductscience.org/library/papers/1557421 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/445479
GET https://conductscience.org/api/papers/v1/445479/authors